Increasing evidence indicates that the expression of cardiac ACE2 is higher following MI, which combats the adverse effects of an activated cardiac RAS and, therefore, may be a compensatory mechanism in MI (8–11,15,20). The gene discussed is ACE2; the disease is myocardial infarction.